Sir AP McCoy and father of late “King of Heswall” team up for Randox Health Week
Almost a year to the day of the tragic death of the “King of Heswall” Tim Cogley, his father will be joined by some of the UK’s best-known sports stars at an event in Liverpool to raise awareness of how lives can be saved through improving access to earlier routine health screening.
On April 9th 2017 Tim, who was only 34-years old, suffered a fatal heart attack due to a genetic condition which could have been managed had it been diagnosed earlier. It spurred his father, Frank Cogley, to set up a charity to raise awareness of the importance of health checks for young people.
He’ll be joined at the free Randox Health Week event in Exchange Station on 11th April by legendary jockey Sir AP McCoy, champion boxer Paul Smith and Olympic sailor Matt McGovern. The public will be invited to join the discussions as well.
Frank said: “It’s been recently reported that at least 12 under-35s die from undiagnosed heart conditions every week in the UK. The current lack of routine screening of 18-40-year olds leaves a gaping chasm in our healthcare provision. With our highly motivated partners, through events like this, we hope to redress this through lifestyle changes and preventative medical programmes. The ‘Tim Cogley Cardiac Screening Foundation’ is committed to delivering positive, action-focused and life-changing programmes. I can’t imagine a legacy more in tune with the generous, kind and supportive person that was Tim!”
This is the second year that Randox Health Week has been held in the city. The areas of mental health and active cities will be explored on days one and two – the 9th and 10th respectively. On each of the mornings, local athletes Franny Norton and Derry Mathews will be putting pupils to the test with a range of sporting activities at LJMU’s Byrom Street campus.
By working with the city’s leading universities – Liverpool John Moores and Liverpool Hope – cutting-edge innovations in healthcare and emerging trends are being shared with a global audience. One such ground-breaking development is a test for prediabetes which is key to tackling the worldwide threat of preventable cases of Type-2 diabetes. It’s something that legendary jockey Sir Anthony McCoy, also taking part in Wednesday’s talk, has first-hand experience of:
“When I got my first test results back that said I had prediabetes, it floored me. I had never imagined that I, someone who had been a professional athlete all of my life, could develop it. It just goes to show that we’re all vulnerable. I only wish it had been around when it could have helped my mum who lived with Type-2 diabetes for many years. As daunting as it was getting the diagnosis, it’s been empowering to very simply make lifestyle changes to reverse it. This needs to be accessible to everyone – it needs to be on the national diabetes screening programme.”
Dr Peter FitzGerald, Managing Director of Randox Health, commented: “The themes we’re focusing on this week are some of the most important global concerns facing us today – mental health, physical activity and showing people the benefits to being proactive about their health, rather than facing the consequences of preventable sickness. You need look no further than Frank Cogley who is working tirelessly to turn his son’s tragic death into a force for good to see how important this is. With the support from AP McCoy and Paul Smith, we hope this event will inspire many people in the city and beyond.”
Tickets are free and can be reserved at www.eventbrite.co.uk/e/randox-health-week-2018-tickets-43648350391
For further information about Randox Health Week, please contact the Randox PR team by email: randoxpr@randox.com or by phone: 028 9442 2413
Biochip Carrier Applications in the Randox Evidence Series
Biochip Array Technology is the fundamental component which drives the Randox Evidence Series immunoanalysers. The simultaneous detection of multiple analytes from a single sample allows for a complete patient profile, providing exceptional time, resource and cost savings.
The Evidence Series analysers all carry the Biochip in different applications. In order to gain a better understanding of how it is utilised, the illustrations below demonstrate how adaptable and flexible the technology is across the Evidence Series.
Evidence Evolution
- One strip contains 10 biochips
- Analyser can hold 20 strips
- Can produce a throughput of up to 2640 tests per hour
Evidence
- Each cassette contains 10 carriers
- Each carrier has 9 wells
- Analyser can hold 4 cassettes at once
- Can produce a throughput of up to 3960 tests per hour
Evidence Investigator
- Analyser holds 1 cartridge
- 1 cartridge contains 9 wells
- Thermoshaker capable of carrying 6 cartridges
- Can produce a throughput of up to 2376 tests per hour
Evidence MultiSTAT
- Analyser holds 1 cartridge
- Cartridge comes pre-loaded with reagents and QC
- Can produce a throughput of up to 132 tests per hour
About the Randox Evidence Series
The Evidence Series is set to revolutionise diagnostic testing forever. Offering unrivalled capabilities across all analysers, we truly believe that the Evidence Series range of immunoassay analysers can meet your diagnostic testing capabilities.
For more information on any of the Evidence Series analysers, visit https://www.randox.com/evidence-series/ or contact us evidenceseries@randox.com.
Evidence MultiSTAT: Fast, Fully Automated and Versatile
The Evidence MultiSTAT is a fully automated immunoanalyser that enables on-site simultaneous detection of up to 44 analytes from a single sample of oral fluid, urine or blood. It requires a small sample volume and generates results in less than 20 minutes. The process from sample entry to results can be completed in 3 simple steps, with minimum room for human error.
The MultiSTAT offers a very simple drug screening solution to those who have no knowledge of laboratory procedures through combining simplicity with cutting-edge innovation. It is this innovative technology that enables the MultiSTAT to be easy to use, yet extremely powerful.
Versatility
Whether testing is needed for new entrants going into prison, or for a drug drive test – the MultiSTAT is adaptable for use across a range of different applications. As an analyser, it can deliver highly accurate and reliable laboratory quality results. Its ability to provide these quickly and over a wide range of substances makes it as flexible as any point of care test. The Evidence MultiSTATs ease of use makes it accessible to all with no previous laboratory experience required.
The Evidence MultiSTAT is a versatile analyser that provides automated drugs screening in a range of settings, such as low throughput laboratories, workplaces and police stations. Using chemiluminescence as a measurement principle, the Evidence MultiSTAT consistently delivers accurate results and offers a highly sensitive way to detect drugs of abuse.
Extensive
The MultiSTAT facilitates on-site simultaneous screening of multiple drug classes, including classical, prescription and synthetic drugs of abuse. Available matrices include oral fluid, with blood and urine coming soon.
Recently, the InfiniPlex for Milk Array has been developed by Randox Food Diagnostics to help the dairy industry improve the global standards of dairy. Complying with 98% of EU regulated antibiotics, InfiniPlex is currently unrivalled in the market with the ability to simultaneously detect anti-parasitics, anti-inflammatories and unauthorised substances found in dairy products from a single sample of raw milk using Biochip Array Technology. With results screened in just under 20 minutes, the Evidence MultiSTAT is ideally suited to the fast-paced nature of the dairy industry.
Developed with the user in mind, no technical expertise is required to use the test and is available on two analysers in the Evidence Series, the Evidence MultiSTAT and Evidence Investigator.
About the Randox Evidence Series
The Evidence Series is set to revolutionise diagnostic testing forever. Offering unrivalled capabilities across all analysers, we truly believe that the Evidence Series range of immunoassay analysers can meet your diagnostic testing capabilities.
For more information on the Evidence MultiSTAT, or any of the Evidence Series analysers, visit https://www.randox.com/evidence-series/ or contact us evidenceseries@randox.com.
From Columbia to the UK: The trail that’s fuelling the worldwide cocaine epidemic
With the demand for cocaine in the UK rocketing, Top British Chef Gordon Ramsay has recently travelled to Columbia to the source of the problem, to learn more about this growing epidemic.
Having spent time with local farmers who own cocaine plants that resemble vineyards, and visiting Honduras, one of the most dangerous countries and known as the world’s warehouse of cocaine, he emphasized the urgent need to combat the drugs industry that is consuming this country.
Highlighted throughout the two-part series was the amount of cocaine that is being trafficked to the shores of the UK each year. Speaking with the metropolitan police who tackle up to 200 drug gangs in London alone, it was estimated that up to 300 tons of cocaine, with a street value of £10 billion, is being brought in to the country through a web of secretive routes used by drug traffickers.
Gordon commented that not only is cocaine a growing global problem, but it is one that is prevalent within the culinary world, including his own restaurants where he has been asked to dust the drug on top of soufflés as icing sugar, and found traces of this deadly drug in both his staff and customer toilets.
With the cocaine problem showing no signs of slowing down, Randox Toxicology are constantly working to develop the newest drug tests to meet the demands of the ever-growing drug market. The Evidence MultiSTAT was developed for use in non-laboratory settings such as workplaces, police stations and low throughput laboratories and to provide highly accurate qualitative as quickly as possible.
This revolutionary analyser enables on-site simultaneous detection of up to 21 classical, prescription and synthetic drugs from a single patient sample, reducing the burden on current systems, the risk of adulteration and helping the fight against the cartels who control the cocaine trade in South America.
For more information on our Evidence Analysers or any of our drug panels email info@randoxtoxicology.com
Welcome to the Evidence Series
Introduction
For over 30 years, we have been researching and manufacturing market-leading diagnostics products globally. With a mission statement of ‘dedicated to improving health worldwide’ the patient needs are a central focus of everything we do. It is this experience and commitment to improving healthcare that has allowed us to continually improve our product offering and make advancements globally to reach as many people as possible and provide greater diagnostic facilities.
From this experience and commitment to research, we believe we have developed a technology that has changed diagnostic testing forever.
Biochip Array Technology
In 2002, we invented a world first, which changed the landscape of diagnostic testing forever. Biochip Array Technology is a precision multiplex testing platform allowing for the simultaneous quantitative or qualitative detection of a wide range of analytes from a single sample.
Biochip Array Technology uniquely offers immunoassay diagnostic testing for simultaneous multi-analyte biomarker detection. After addition of a single patient sample to the biochip, analytes present in the sample bind to the specific biochip bound ligands. The degree of binding is determined using a chemiluminescent light source and quantified using a Charge Coupled Device (CCD) camera and imaging system.
An individual biochip has up to 49 Discrete Test Regions with each detecting a different biomarker. That means up to 44 tests can be carried out simultaneously, with the additional DTRs being reserved for visual quality control and visual reference; a feature unique to Biochip Array Technology.
The Evidence Series
Having developed this patented technology following £250 million investment in research and development, we needed a platform that allowed Biochip Array Technology capabilities to be showcased. Step forward the Evidence Series. The series includes the Evidence, the Evidence Evolution, the Evidence Investigator and the Evidence MultiSTAT. Each analyser has been designed and built with boundary pushing engineering, to ensure financial, labour and time savings for the end user.
Have a read below of the brief overview of each analyser in the Evidence Series
Evidence Evolution
The world’s first fully automated random-access biochip testing platform, the Evidence Evolution is the world’s most advanced immunoanalyser. With the capability to process up to 2,640 tests per hour, the Evidence Evolution offers complete system integration, as well as the most comprehensive test menu on the market.
Evidence
As the world’s first Biochip Array Technology system, the Evidence immunoanalyser has revolutionised laboratory screening worldwide. With the capability to process 3,960 tests per hour and a sample capacity of 360, the Evidence is ideal for use in a high throughput laboratory.
Evidence Investigator
The Evidence Investigator is a compact, semi-automated benchtop immunoanalyser that offers efficient and comprehensive testing across a range of applications including clinical diagnostics, molecular, toxicology and food diagnostics. The Evidence Investigator boasts a throughput of up to 2,376 tests per hour, offering efficiency without compromising on accuracy.
Evidence MultiSTAT
The Evidence MultiSTAT is a fully automated immunoanalyser that enables on-site simultaneous detection of up to 44 analytes from a single sample of oral fluid, urine or blood. With a three-step process and results generated in less than 20 minutes, the Evidence MultiSTAT is an ideal solution for those with no knowledge of laboratory procedures and offers a throughput of up to 132 tests per hour.
About the Randox Evidence Series
The Evidence Series is set to revolutionise diagnostic testing forever. Offering unrivalled capabilities across all analysers, we truly believe that the Evidence Series range of immunoassay analysers can meet your diagnostic testing capabilities. For more information on any of the Evidence Series analysers, please visit http://www.randox.com/evidence-series/ or contact us evidenceseries@randox.com.
Evidence Series Immunoanalysers
Powered by Biochip Array Technology
In 2002, Randox invented a world first, Biochip Array Technology (BAT), instantly changing the landscape of diagnostic testing forever. BAT is a multi-analyte platform which provides an unrivaled increase in patient information per sample. Instead of a patient sample needing to be subdivided for each test result, or in some cases re-collected, Biochip Array Technology offers a diagnostic patient profile with each patient sample. So now the patient’s needs become the focus, as BAT delivers the multiple results needed for improved diagnosis.
With over £250 million invested into Biochip Array Technology research and development, Randox have launched a range of Biochip Array Technology immunoanalysers – The Evidence Series. This includes the Evidence, the Evidence Investigator and the Evidence MultiSTAT. Each analyser is developed with boundary pushing engineering, designed to make financial, labour and time savings for the end user. Utilising this technology, the Evidence series guarantees cost-effective, highly accurate and flexible testing solutions.
Click on the immunoanalysers below for more information
Evidence Investigator
Evidence MultiSTAT
Evidence
Why choose the Evidence Series?
Biochip Array Technology Test Menu
Adhesion Molecules
| E-Selectin | P-Selectin | L-Selectin | |
| Intercellular Adhesion Molecule-I – ICAM-I | Vascular Cell Adhesion Molecule-I –VCAM-I | ||
Alzheimer’s
| Apolipoprotein E4 –ApoE4 | Pan Apolipoprotein E – Apo E |
Anaemia
| Ferritin | Folate | Vitamin B12 |
Bone Disease
| Vitamin D | |||
Cancer
| Carcinoembryonic Antigen – CEA | Free Prostate Specific Antigen − FPSA | Total Prostate Specific Antigen − TPSA | |
Cardiac
| Cardiac Troponin I – cTnl | Creatine Kinase MB – CKMB | Heart Fatty Acid Binding Protein – H-FABP | Myoglobin |
Cerebral
| Brain-Derived Neurotrophic Factor − BDNF | Neuron Specific Enolase − NSE | ||
Cytokines
| Epidermal Growth Factor − EGF | Granulocyte Macrophage Colony Stimulating Factor | Interferon-γ − IFN-γ | Interleukin-1 alpha − IL-1α |
| Interleukin-1 beta − IL-1β | Interleukin-2 − IL-2 | Interleukin-3 − IL-3 | Interleukin-4 − IL-4 |
| Interleukin-5 − IL 5 | Interleukin-6 − IL-6 | Interleukin-7 − IL-7 | Interleukin-8 − IL-8 |
| Interleukin-4 − IL-4 | Interleukin-5 − IL 5 | Interleukin-6 − IL-6 | Interleukin-7 − IL-7 |
| Interleukin-8 − IL-8 | Interleukin-10 − IL-10 | Interleukin-12p70 − IL-12p70 | Interleukin-13 − IL-13 |
| Interleukin-15 − IL 15 | Interleukin-23 − IL-23 | Macrophage Infl ammatory Protein-1α − MIP-1α | Matrix Metalloproteinase 9 − MMP 9 |
| Monocyte Chemotactic Protein-1 − MCP-1 | Soluble IL-2 Receptor Alpha − sIL-2Rα | Soluble IL-6 Receptor − sIL-6R | Soluble Tumour Necrosis Factor Receptor 1 − sTNFR1 |
| Soluble Tumour Necrosis Factor Receptor 2 − sTNFR2 | Tumour Necrosis Factor-α − TNF-α | Vascular Endothelial Growth Factor − VEGF | |
Diabetes
| Insulin | |||
Endocrine
| Cortisol | Dehydroepiandrosterone-Sulphate- DHEAS | ||
Fertility / Pregnancy
| Estradiol | Follicle Stimulating Hormone − FSH | Luteinizing Hormone − LH | Progesterone |
| Prolactin | Sex Hormone Binding Globulin − SHBG | Testosterone | |
Fibrinolysis
| D-Dimer |
Gastro
| Gastrin 17 – GI7 | Helicobacter pylori – H. pylori | Pepsinogen I – PGI | Pepsinogen II – PGII |
Metabolic
| Adiponectin | Ferritin | Insulin | Leptin |
| Plasminogen Activator Inhibitor − PAI-1 | Resistin |
Renal
| Adiponectin | Complement C3a des Arginine – C3a des Arg | CRP (C-Reactive Protein) | Cystatin C |
| D-Dimer | Epidermal Growth Factor − EGF | Fatty Acid Binding Protein-1 − FABP1 | Interleukin-8 − IL-8 |
| Macrophage Infl ammatory Protein-1α − MIP-1α | Neutrophil Gelatinase – Associated Lipocalin – NGAL | Soluble Tumour Necrosis Factor Receptor 1 − sTNFR1 | Soluble Tumour Necrosis Factor Receptor 2 − sTNFR2 |
Stroke
| Brain-Derived Neurotrophic Factor − BDNF | D-Dimer | Glial Fibrillary Acidic Protein − GFAP | Glutathione S – Transferase Pi – GSTPi |
| Heart Fatty Acid Binding Protein – H-FABP | Interleukin-6 − IL-6 | Nucleoside Diphosphate Kinase – NDKA | Neuron Specifi c Enolase − NSE |
| Parkinson Protein 7 − PARK-7 | Soluble Tumour Necrosis Factor Receptor 1 − sTNFR1 | ||
Thyroid
| Anti-Thyroglobulin − Anti-Tg | Anti-Thyroid Peroxidase − Anti-TPO | Free Tri-iodothyronine − FT3 | Free Thyroxine − FT4 |
| Thyroid Stimulating Hormone − TSH | Thyroxine Binding Globulin − TBG | Total Tri-iodothyronine − TT3 | Total Thyroxine − TT4 |
Toxicology
| Amphetamine | Barbiturates | Benzodiazepines I | Benzodiazepines II |
| Buprenorphine | Cannabinoids – THC | Cocaine Metabolite | Dextromethorphan |
| Fentanyl | Ketamine | Meprobamate | Methadone |
| Opiate | Oxycodone I | Oxycodone II | Phencyclidine – PCP |
| Tramadol | Tricyclic Antidepressants | Zolpidem | |
Molecular
| 20 SNPs | Adenovirus A/B/C/D/E | APOB – 1 mutation | Bordetella pertussis |
| BRAF – 1 mutation | Chlamydia trachomatis – (CT) | Chlamydophila pneumoniae | Coronavirus 229E/NL63 |
| Coronavirus OC43/HKU1 | Enterovirus A/B/C | Haemophilus ducreyi – (HD) | Haemophilus influenzae |
| Herpes simplex Virus 1– (HSV-1) | Herpes simplex Virus 2 – (HSV-2) | Human Bocavirus 1/2/3 | Human Metapneumovirus – hMPV |
| Influenza A/B | KRAS – 16 mutations | LDLR – 38 mutations | Legionella pneumophila |
| Moraxella catarrhalis | Mycoplasma genitalium – (MG) | Mycoplasma hominis – (MH) | Mycoplasma pneumoniae |
| Neisseria gonorrhoea – (NG) | Parainfluenza Virus 1/2/3/4 | PCSK9 – 1 mutation | PIK3CA – 3 mutations |
| Respiratory Syncytial Virus a – RSVa | Respiratory Syncytial Virus b – RSVb | Rhinovirus A/B | Streptococcus pneumoniae |
| Treponema pallidum – (TP) | Trichomonas vaginalis – (TV) | Ureaplasma urealyticum – (UU) | |
Veterinary Residues / Food Diagnostics
| 17β-Clostebol | 5-hydroxy Flunixin | Aflatoxin B1 | Aflatoxin G1/G2 |
| Aflatoxin M1 | AHD | Amikacin/Kanamycin | Amino Benzimidazoles |
| Amoxicillin | AMOZ | Amphenicols | Ampicillin |
| AOZ | Apramycin | Avermectins | Bacitracin |
| Baquiloprim | Benzimidazoles | Beta-agonists | Beta-Lactams |
| Boldenone | Cefapirin | Cefoperazone | Cefquinome |
| Ceftiofur | Cefuroxime | Cephalexin | Cephalonium |
| Chloramphenicol | Chlormadinone | Clopidol | Cloxacillin |
| Corticosteroids | Dapsone | Decoquinate | Deoxynivalenol |
| Dexamethasone | Diacetoxyscirpenol | Diclazuril | Dicloxacillin |
| Dihydrostreptomycin | Ergot Alkaloids | Erythromycin | Ethinylestradiol |
| Fumonisins | Gentamicin | Gestagens | Halofugine |
| Hygromycin B | Imidocarb | Kanamycin | Lasalocid |
| Levamisole | Lincomycin | Lincosamides | MaduramicinG |
| Melamine | Meloxicam | Metamizole | Methyltestosterone |
| Monensin | Moxidectin (MXD) | Nandrolone | Neomycin/Paromomycin |
| Nicarbazin | Nitroimidazoles | Nitroxynil | Novobiocin |
| Ochratoxin A | Oxacillin | Paxilline | Penicillin G |
| Penicillin V | Phenylbutazone | Pirlimycin | Polymixins |
| Quinolones | Ractopamine | Rifaximin | Robenidine |
| Salinomycin | SEM | Spectinomycin | Spiramycin |
| Spiramycin/Josamycin | Stanozolol | Stilbenes | Streptomycin |
| Sulfaguanidine | Sulfamethazine | Sulphachlorpyridazine | Sulphadiazine |
| Sulphadimethoxine | Sulphadoxine | Sulphamerazine | Sulphamethazine |
| Sulphamethizole | Sulphamethoxazole | Sulphamethoxypyridazine | Sulphapyridine |
| Sulphaquinoxaline | Sulphathiazole | Sulphisoxazole | Sulphonamides |
| T2 toxin | Tetracyclines | Thiabendazole | Thiamphenicol |
| Tobramycin | Tolfenamic Acid | Toltrazuril | Trenbolone |
| Triclabendazole | Trimethoprim | Tylosin | Tylosin B/Tilmicosin |
| Virginiamycin | Virginiamycin M1 | Zearalenone | Zeranol |
Evidence Series Enquiry
Enquire to find out more about our Biochip powered Evidence Series immunoanalysers
Evidence MultiSTAT – Biochip Immunoanalyser
Fast. Fully Automated. Versatile.
The Evidence MultiSTAT is a fully automated immunoanalyser that enables on-site simultaneous detection of up to 44 analytes from a single sample of oral fluid, urine or blood. It requires a small sample volume and generates results in less than 20 minutes. The process from sample entry to results can be completed in 3 simple steps, with minimum room for human error. The process is designed to make set up and analysis as quick, simple and reliable as possible.
The MultiSTAT offers a very simple drug screening solution to those who have no knowledge of laboratory procedures through combining simplicity with cutting-edge innovation. It is this innovative technology that enables the MultiSTAT to be easy to use, yet extremely powerful.
- Fully automated benchtop immunoanalyser
- Up to 132 tests per hour
- Results generated in 17 minutes
- Up to 44 analytes screened per biochip
- 3 steps from sample entry to results
- No laboratory / laboratory experience required to operate
- Suitable for use in a range of laboratory and non-laboratory settings
- 59cm (H) x 54cm (D) x 57cm (W)
Evidence MultiSTAT Test Menu
| AB-PINACA | Benzodiazepines II | EtG | Ketamine | TCA |
| Amphetamine | Buprenorphine | Fentanyl | LSD | UR-144 / XLR II |
| a-PVP | BZG/Cocaine | Methadone | Opiates | JWH-018 |
| Barbiturates | Cannabinoids | Methamphetamine | Oxycodone | 6 MAM |
| Benzodiazepines I | Dextromethorphan | Creatinine | Tramadol | PCP |
